• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

LHCGR sirna

Scan QR to view Datasheet
Catalog # MBS828910
Unit / Price
Scan QR to view Datasheet
  15 nmol  /  $365 +1 FREE 8GB USB
  30 nmol  /  $515 +1 FREE 8GB USB
LHCGR sirna
Product Name


Popular Item
Full Product Name

LHCGR siRNA (Mouse)

Product Synonym Names
LHR; Lutropin-choriogonadotropic hormone receptor; LH/CG-R; Luteinizing hormone receptor; LSH-R
Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P30730
Species Reactivity
LHCGR siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
> 97%
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse LHCGR gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of LHCGR sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
LHCGR sirna
siRNA to inhibit LHCGR expression using RNA interference
Applications Tested/Suitable for LHCGR sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for LHCGR. It may not necessarily be applicable to this product.
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Related Accession #
Molecular Weight
78,215 Da
NCBI Official Full Name
lutropin-choriogonadotropic hormone receptor
NCBI Official Synonym Full Names
luteinizing hormone/choriogonadotropin receptor
NCBI Official Symbol
Lhcgr  [Similar Products]
NCBI Official Synonym Symbols
Lhr; LH-R; Gpcr19-rs1
  [Similar Products]
NCBI Protein Information
lutropin-choriogonadotropic hormone receptor
UniProt Protein Name
Lutropin-choriogonadotropic hormone receptor
UniProt Synonym Protein Names
Luteinizing hormone receptor; LSH-R
UniProt Gene Name
Lhcgr  [Similar Products]
UniProt Synonym Gene Names
Lhr; LH/CG-R; LSH-R  [Similar Products]
UniProt Entry Name
UniProt Comments for LHCGR
LHR: Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Defects in LHCGR are a cause of familial male precocious puberty (FMPP); also known as testotoxicosis. In FMPP the receptor is constitutively activated. Defects in LHCGR are the cause of luteinizing hormone resistance (LHR); also known as Leydig cell hypoplasia in males. LHR is an autosomal recessive disorder characterized by unresponsiveness to luteinizing hormone, defective sexual development in males, and defective follicular development and ovulation, amenorrhea and infertility in females. Two forms of the disorder have been defined in males. Type 1 is a severe form characterized by complete 46,XY male pseudohermaphroditism, low testosterone and high luteinizing hormone levels, total lack of responsiveness to luteinizing and chorionic gonadotropin hormones, lack of breast development, and absent development of secondary male sex characteristics. Type 2, a milder form, displays a broader range of phenotypic expression ranging from micropenis to severe hypospadias. Belongs to the G-protein coupled receptor 1 family. FSH/LSH/TSH subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Receptor, GPCR; GPCR, family 1; Membrane protein, multi-pass; Membrane protein, integral

Cellular Component: extracellular space; membrane; endoplasmic reticulum; lysosome; integral to plasma membrane; cytoplasm; integral to membrane; plasma membrane; nucleus; receptor complex; endosome

Molecular Function: lutropin-choriogonadotropic hormone receptor activity; G-protein coupled receptor activity; identical protein binding; signal transducer activity; protein homodimerization activity; peptide hormone binding; protein-hormone receptor activity; peptide receptor activity, G-protein coupled; ATPase binding

Biological Process: protein targeting to lysosome; hormone-mediated signaling; male gonad development; adenylate cyclase activation; positive regulation of inositol trisphosphate biosynthetic process; positive regulation of calcium-mediated signaling; luteinizing hormone signaling pathway; uterus development; signal transduction; arachidonic acid secretion; ovulation cycle process; G-protein signaling, coupled to cAMP nucleotide second messenger; G-protein coupled receptor protein signaling pathway; ovarian follicle development; positive regulation of hormone biosynthetic process; development of secondary male sexual characteristics; spermatogenesis; G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); positive regulation of release of sequestered calcium ion into cytosol; cognition; female gonad development
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Organs/Tissues associated with LHCGR sirna
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.